A recent phase-2 clinical trial regarding the safety and effectiveness of a BET inhibitor (ZEN-3694) in squamous cell lung cancer patients with NSD3 amplification is currently ongoing (http://www.clinicaltrials.gov (accessed on 2 January 2024), identifier NCT05607108). Here, NSD3 is linked to squamous cell lung carcinoma.